Aurora Cannabis (ACB) Shows Volatility and Potential Upside

Company Overview

Aurora Cannabis Inc. (Ticker: ACB) specializes in the production, distribution, and sale of cannabis in Canada. Their operations extend over 25 countries across five continents. ACB is listed on the NASDAQ stock exchange.

Technical Analysis

Aurora Cannabis closed at $0.91 on September 11, 2023. The stock gained 72.17% in a sudden surge, thereby showing considerable volatility. The difference between the day's high and low prices was significant at $0.38.

The stock's 50 Day Moving Average at $0.52 and the 200 Day Moving Average at $0.74 suggests that ACB has been trending upwards over time despite recent volatility. In comparison, despite the differences in the daily closing price, the MACD 3-month change indicates the possibility of a bearish trend. ACB has an overbought RSI index of 85, which may indicate potential for a price correction.

In the absence of any identifiable support and resistance levels, it is challenging to predict price actions based on this measure. The ATR ratio, which measures volatility, is at 6.89, high for a company of ACB's size, which signifies notable price fluctuations.

Fundamental Analysis

Despite a notably high trading volume, Aurora Cannabis carries a negative EPS of -$6.5. ACB’s Price to Earnings (P/E) ratio is also in negative territory at -0.14, suggesting the company is not profitable at this time. These indicators could be a source of concern for potential investors.

However, recent news suggests Aurora Cannabis may have a promising future. Aurora Cannabis is reportedly focusing on paying down debt and has promised positive free cash flow (FCF) in 2024. Earlier predictions didn't expect the company to achieve this milestone until 2026.

Analysis further indicates that the passing of the SAFE Banking Act would yield a positive outcome for ACB, primarily due to the positive performance of cannabis stocks following potential drug reclassification. The legislation would allow financial institutions to offer loans and other banking services to legal cannabis businesses, an eventuality that is said to have been factored into the share’s pricing.

Outlook and Recommendation

Based on the consensus from 7 analysts, the stock is categorized as a "Hold", with one analyst advising a "buy". The consensus target price is $5.92 with a high estimate of $8.75 and a low estimate of $1.

Given the highly speculative nature of the stock, the recommendation is to 'Hold', owing to its potential upside, as reflected in the analysts' consensus target price. However, investors are advised to keep an eye on developments surrounding the company’s commitment to achieving positive FCF in 2024 and potential legislation changes in the cannabis sector.

Predictions

For the next trading day, due to currently being overbought and exceptionally high target price, a moderate correction might be anticipated. Given the high volatility of the stock, it is difficult to predict its performance for the upcoming week. Nevertheless, as the company is on the verge of positive cash flow and prospective industry legislation, it could potentially witness upward movement in the longer term.

Please note that the Health and Human Services (HHS) asking the Drug Enforcement Administration (DEA) to reclassify Marijuana from Schedule I to Schedule III fields broader sectoral optimism which may support the stock price in the near future.

However, these predictions should be interpreted with caution and used as a guide alongside other market evaluation tools.